Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Phase IV Studies Need Greater Input From FDA, Industry Tells IoM Panel

Jan 30 2006

• By The Pink Sheet

Related Content

Exubera’s Post-Marketing Safety Program Is Industry Model – Pfizer’s Ryder

Jan 23 2006

FDA May Seek More Authority To Require Post-Marketing Safety Studies

Aug 01 2005

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window